Amplyx Pharmaceuticals competitors

Amplyx Pharmaceuticals Competitors include Cantabio Pharmaceuticals, XOMA, Novartis and Bristol-Myers Squibb.
Add company...
Cantabio Pharmaceuticals
Cantabio Pharmaceuticals
Cantabio Pharmaceuticals Inc. is a biotechnology company focusing on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases.
XOMA
XOMA
XOMA is a biotechnology company discovering, developing and commercializing antibody-based therapeutics.
Novartis
Novartis
Novartis researches, develops, manufactures, and markets a range of healthcare products.
Bristol-Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Founding Date
Founding Date
2006
Founding Date
2009
Founding Date
1981
Founding Date
1996
Founding Date
1887
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
San Diego, US HQ
Locations
Sunnyvale, US HQ
Locations
Emeryville, US HQ
Locations
Basel, CH HQ
Núñez, AR
Elsene, BE
São Paulo, BR
Dorval, CA
Chaoyang Qu, CN
Praha 4, CZ
see more
Locations
New York, US HQ
Vienna, AT
Braine L'alleud, BE
Calgary, CA
Edmonton, CA
Montreal, CA
Toronto, CA
see more
Employees
Employees
29
Employees
11
Employees
1233% decrease
Employees
126,0004% increase
Employees
23,700
Valuation ($)
Valuation ($)
N/A
Valuation ($)
1.1 m
Valuation ($)
114.2 m
Valuation ($)
175.5 b
Valuation ($)
81.8 b
Twitter followers
Twitter followers
N/A
Twitter followers
803
Twitter followers
185
Twitter followers
234.4 k
Twitter followers
120.8 k

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$52.7m (FY, 2017)
Revenue (est.)
$49.1b (FY, 2017)
Revenue (est.)
$20.8b (FY, 2017)
Cost of goods
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$17.2b (FY, 2017)
Cost of goods
$6.1b (FY, 2017)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
$31.9b (FY, 2017)
Gross profit
$14.7b (FY, 2017)
Net income
Net income
N/A
Net income
($2m) (FY, 2018)
Net income
N/A
Net income
$7.7b (FY, 2017)
Net income
$975m (FY, 2017)

Operating

Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
29 (Y, 2016)
Phase III Trials Products
8 (FY, 2016)

Funding

Total funding raised
Total funding raised
$ 116.2m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 6.5m
Total funding raised
$ 15.5m
For sources of this data, please see the company profileDownload Excel

View company profiles

Cantabio Pharmaceuticals
HQ
Sunnyvale, US
Employees
11

Cantabio Pharmaceuticals Inc. is a biotechnology company focusing on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases.

View company
XOMA
HQ
Emeryville, US
Employees
12↓ 33% decrease

XOMA is a biotechnology company discovering, developing and commercializing antibody-based therapeutics.

View company
Novartis
HQ
Basel, CH
Employees
126,000↑ 4% increase

Novartis researches, develops, manufactures, and markets a range of healthcare products.

View company
Bristol-Myers Squibb
HQ
New York, US
Employees
23,700

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

View company